期刊文献+

吉非替尼治疗老年晚期非小细胞肺癌40例分析 被引量:1

原文传递
导出
摘要 目的:观察吉非替尼治疗老年晚期非小细胞肺癌临床疗效及不良反应。方法:40例患者,口服吉非替尼治疗,250 mg/d。结果:CR 2例,PR 10例,SD 11例,PD 17例,疾病控制率57.5%。不良反应为唑疮样皮疹46.7%(18/40),转氨酶升高7.14%(3/42)。结论:吉非替尼治疗老年晚期非小细胞肺癌疗效好,不良反应较微,能明显改善患者生活质量。
出处 《中国误诊学杂志》 CAS 2009年第15期3710-3710,共1页 Chinese Journal of Misdiagnostics
  • 相关文献

参考文献4

二级参考文献57

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:625
  • 2[1]Gatzemeier U,Groth G,Butts C,et al.Randomized phase Ⅱ trial of gemcitabine-cisplatin with or without trastuzumab in HER-2-positive non-small cell lung cancer.Ann Oncol,2004,15:3
  • 3[2]Villalona-Calero MA,Ritch P,Figueroa JA,et al.A phase Ⅰ/Ⅱ study of LY900003,an antisense inhibitor kinase C-alpha,in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.Clin Cancer Res,2004,10:6086
  • 4[3]Paz-Ares L,Douillard J Y,Koralewski P,et al.Phase Ⅲ study of gemcitabine and cisplatin with or without aprinocarsen,a protein kinase C-alpha antisense oligonucleotide in patients with advanced-stage non-small cell lung cancer.J Clin Oncol,2006,20:1428
  • 5[4]Altorki NK,Keresztes RS,Port JL,et al.Celecoxib,a selective cyclo-oxygenase-2 inhibitor,enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer.J Clin Oncol,2003,21 (14):2645
  • 6[5]Fukuoka M,Yano S,Giaccone G,et al.Multi-institutional randomized phase Ⅱ trial of gefitinib for previously treated patients with advanced non-small cell lung cancer.J Clin Oncol,2003,21:223746
  • 7[6]Kris MG,Natsle RB,Herbst RS,et al.Efficacy of gefitinib,an inhibitor of the epidermal growth factor receptor tyrosine kinase,in symptomatic patients with non-small cell lung cancer:A randomized trial.JAMA,2003,290:214958
  • 8[7]Perez-Soler R,Chachou A,Huberman M,et al.A Phase Ⅱ trial of the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774,following platinum-based chemotherapy,in patients with advanced,EGFR-expressing,nonsmall cell lung cancer.Proc Am Soc Clin Oncol,2001,1235A
  • 9[8]Shepherd FA,Pereira J,Ciuleanu TE,et al.A randomizedplacebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy.A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trial.2004 ASCO Annual Meeting,Late-Breaking Abstracts Booklet,Abstract 7022
  • 10[9]Gefitinib (Iressa) Lung Cancer ISEL Trial shows no overall survival advantage in a highly refractory population.Astrazeneca Press Release,2004.http://www.astrazeneca.com/pressrelease/4245.aspx,accessed 21/03/05

共引文献33

同被引文献8

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部